IRIS Accounts Production v23.3.0.418 09904280 Board of Directors Board of Directors Board of Directors 1.7.22 31.12.22 31.12.22 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh099042802022-06-30099042802022-12-31099042802022-07-012022-12-31099042802020-12-31099042802021-01-012022-06-30099042802022-06-3009904280ns10:Originalns15:EnglandWales2022-07-012022-12-3109904280ns14:PoundSterlingns10:Original2022-07-012022-12-3109904280ns10:Originalns10:Director12022-07-012022-12-3109904280ns10:Original2022-07-012022-12-3109904280ns10:Originalns10:Director22022-07-012022-12-3109904280ns10:Originalns10:Director32022-07-012022-12-3109904280ns10:Original2022-12-3109904280ns10:Originalns10:PrivateLimitedCompanyLtd2022-07-012022-12-3109904280ns10:Originalns10:SmallEntities2022-07-012022-12-3109904280ns10:Originalns10:AuditExempt-NoAccountantsReport2022-07-012022-12-3109904280ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-07-012022-12-3109904280ns10:SmallCompaniesRegimeForAccountsns10:Original2022-07-012022-12-3109904280ns10:Originalns10:FullAccounts2022-07-012022-12-3109904280ns10:Originalns10:OrdinaryShareClass12022-07-012022-12-3109904280ns10:Originalns10:Director42022-07-012022-12-3109904280ns10:CompanySecretary1ns10:Original2022-07-012022-12-3109904280ns10:Originalns10:RegisteredOffice2022-07-012022-12-3109904280ns10:Original2022-06-3009904280ns10:Originalns5:CurrentFinancialInstruments2022-12-3109904280ns10:Originalns5:CurrentFinancialInstruments2022-06-3009904280ns5:ShareCapitalns10:Original2022-12-3109904280ns5:ShareCapitalns10:Original2022-06-3009904280ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-12-3109904280ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-06-3009904280ns10:Original2021-01-012022-06-3009904280ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3109904280ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-06-3009904280ns10:Originalns5:CurrentFinancialInstruments2022-07-012022-12-3109904280ns10:Originalns10:OrdinaryShareClass12022-12-31
REGISTERED NUMBER: 09904280 (England and Wales)













Unaudited Financial Statements

For The Period 1 July 2022 to 31 December 2022

for

MEDSOLUTIONS (EUROPE) LIMITED

MEDSOLUTIONS (EUROPE) LIMITED (REGISTERED NUMBER: 09904280)






Contents of the Financial Statements
For The Period 1 July 2022 to 31 December 2022




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


MEDSOLUTIONS (EUROPE) LIMITED

Company Information
For The Period 1 July 2022 to 31 December 2022







DIRECTORS: M A Khan
A Sharma
Mrs J K Ahluwalia
J Pradyuman Jani





SECRETARY: M A Khan





REGISTERED OFFICE: 79 College Road
Harrow
Middlesex
HA1 1BD





REGISTERED NUMBER: 09904280 (England and Wales)





ACCOUNTANTS: Ayman Tyler Associates
Accountants & Tax Advisers
79 College Road
Harrow
Middlesex
HA1 1BD

MEDSOLUTIONS (EUROPE) LIMITED (REGISTERED NUMBER: 09904280)

Balance Sheet
31 December 2022

31.12.22 30.6.22
Notes £    £   
CURRENT ASSETS
Debtors 4 216,690 62,311
Cash at bank 103,521 29
320,211 62,340
CREDITORS
Amounts falling due within one year 5 273,865 15,261
NET CURRENT ASSETS 46,346 47,079
TOTAL ASSETS LESS CURRENT
LIABILITIES

46,346

47,079

CAPITAL AND RESERVES
Called up share capital 6 200 200
Retained earnings 46,146 46,879
SHAREHOLDERS' FUNDS 46,346 47,079

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2022.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 October 2023 and were signed on its behalf by:




M A Khan - Director J Pradyuman Jani - Director




A Sharma - Director


MEDSOLUTIONS (EUROPE) LIMITED (REGISTERED NUMBER: 09904280)

Notes to the Financial Statements
For The Period 1 July 2022 to 31 December 2022

1. STATUTORY INFORMATION

Medsolutions (Europe) Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 4 (2022 - 4 ) .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.22 30.6.22
£    £   
Trade debtors 216,490 -
Other debtors 200 62,311
216,690 62,311

MEDSOLUTIONS (EUROPE) LIMITED (REGISTERED NUMBER: 09904280)

Notes to the Financial Statements - continued
For The Period 1 July 2022 to 31 December 2022

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.22 30.6.22
£    £   
Trade creditors - 968
Taxation and social security 11,057 11,057
Other creditors 262,808 3,236
273,865 15,261

Other creditors includes cost of sales accrual of £250,000, £6,797 outstanding to LM Manufacturing Ltd and £2,036 due to MA Khan.

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.12.22 30.6.22
value: £    £   
200 Ordinary 1 200 200

Full details of shareholders are as follows:

56 Ordinary shares held by Anil Kumar Sharma
20 Ordinary shares held by Dheeraj Singh Ahluwalia
20 Ordinary shares held by Jagjeet Kaur Ahluwalia
36 Ordinary shares held by JAJ Pharma Limited
18 Ordinary shares held by JSM Innovations Limited
20 Ordinary shares held by Udaya Sharma
30 Ordinary shares held by Eiman Pharma Limited